Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Erica L. Mayer, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA168504 (WINER, ERIC P) Sep 17, 2013 - May 31, 2024
    NIH/NCI
    Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Filho OM, Giobbie-Hurder A, Lin NU, Faggen M, Come S, Openshaw T, Constantine M, Walsh J, Freedman RA, Schneider B, Burstein HJ, Mayer EL. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Oct 06. PMID: 33025482.
    Citations:    
  2. Freret TS, Exman P, Mayer EL, Little SE, Economy KE. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy. Am J Perinatol. 2020 Sep 24. PMID: 32971558.
    Citations:    
  3. Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 Aug 13. PMID: 32798689.
    Citations:    
  4. Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 Jun 01; 26(11):2556-2564. PMID: 32170028.
    Citations:    
  5. Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 May 10; 38(14):1539-1548. PMID: 32097092.
    Citations:    
  6. Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520. PMID: 31987407.
    Citations:    
  7. Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 May 01; 26(9):2111-2123. PMID: 31822498.
    Citations:    
  8. Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520. PMID: 31250880.
    Citations:    
  9. Lee GE, Rosenberg SM, Mayer EL, Borges V, Meyer ME, Schapira L, Come SE, Partridge AH. Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. Breast J. 2019 11; 25(6):1104-1110. PMID: 31318125.
    Citations:    
  10. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. PMID: 31235441.
    Citations:    
  11. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580. PMID: 30880072.
    Citations:    
  12. Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ. Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record. J Oncol Pract. 2018 07; 14(7):e421-e428. PMID: 29939808.
    Citations:    Fields:    
  13. Brown JC, Yung RL, Gobbie-Hurder A, Shockro L, O'Connor K, Campbell N, Kasper J, Mayer EL, Tolaney SM, Partridge AH, Ligibel JA. Randomized trial of a clinic-based weight loss intervention in cancer survivors. J Cancer Surviv. 2018 04; 12(2):186-195. PMID: 29101711.
    Citations:    Fields:    
  14. Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, G?mez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017 Aug 09; 9(402). PMID: 28794284.
    Citations: 3     Fields:    Translation:HumansCells
  15. Wander SA, Mayer EL, Burstein HJ. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870. PMID: 28580881.
    Citations: 5     Fields:    Translation:Humans
  16. Lee GE, Mayer EL, Partridge A. Prognosis of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(3):417-421. PMID: 28365832.
    Citations: 1     Fields:    Translation:Humans
  17. Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res. 2017 Aug 01; 23(15):4035-4045. PMID: 28270498.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  18. Johnson KE, Forward JA, Tippy MD, Ceglowski JR, El-Husayni S, Kulenthirarajan R, Machlus KR, Mayer EL, Italiano JE, Battinelli EM. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis. Arterioscler Thromb Vasc Biol. 2017 04; 37(4):664-674. PMID: 28153880.
    Citations: 8     Fields:    Translation:HumansCells
  19. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Mar 10; 35(8):893-911. PMID: 27918725.
    Citations: 34     Fields:    Translation:Humans
  20. Irwin ML, Cartmel B, Harrigan M, Li F, Sanft T, Shockro L, O'Connor K, Campbell N, Tolaney SM, Mayer EL, Yung R, Freedman RA, Partridge AH, Ligibel JA. Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. Cancer. 2017 Apr 01; 123(7):1249-1258. PMID: 27893938.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  21. Mayer EL, Burstein HJ. Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 10 01; 34(28):3369-71. PMID: 27551109.
    Citations: 1     Fields:    Translation:Humans
  22. Caragacianu DL, Mayer EL, Chun YS, Caterson S, Bellon JR, Wong JS, Troyan S, Rhei E, Dominici LS, Economy KE, Tung NM, Schapira L, Partridge A, Calvillo KZ. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. J Surg Oncol. 2016 Aug; 114(2):140-3. PMID: 27392534.
    Citations: 1     Fields:    Translation:Humans
  23. Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Oncologist. 2016 06; 21(6):666-70. PMID: 27107002.
    Citations: 1     Fields:    Translation:Humans
  24. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975.
    Citations: 20     Fields:    Translation:Humans
  25. Mayer EL, Burstein HJ. Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8. PMID: 26279133.
    Citations: 2     Fields:    Translation:Humans
  26. Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319. PMID: 26211823.
    Citations: 1     Fields:    Translation:Humans
  27. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, Iliescu C, Ky B, Mayer EL, Okwuosa TM, Plana JC, Ryan TD, Rzeszut AK, Douglas PS. Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015 Jun 30; 65(25):2739-46. PMID: 26112199.
    Citations: 20     Fields:    Translation:Humans
  28. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9. PMID: 26056183.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  29. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9. PMID: 25847936.
    Citations: 56     Fields:    Translation:HumansCTClinical Trials
  30. Mayer EL. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer. Clin Adv Hematol Oncol. 2015 Apr; 13(4):215-7. PMID: 26352578.
    Citations:    Fields:    Translation:Humans
  31. Mayer EL, Dominici LS. Breast cancer axillary staging: much ado about micrometastatic disease. J Clin Oncol. 2015 Apr 01; 33(10):1095-7. PMID: 25713441.
    Citations:    Fields:    Translation:Humans
  32. Mayer EL. Targeting breast cancer with CDK inhibitors. Curr Oncol Rep. 2015; 17(5):443. PMID: 25716100.
    Citations: 19     Fields:    Translation:Humans
  33. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105. PMID: 25524311.
    Citations: 13     Fields:    Translation:HumansCells
  34. Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30. PMID: 25205424.
    Citations: 2     Fields:    Translation:HumansCells
  35. Gropper AB, Calvillo KZ, Dominici L, Troyan S, Rhei E, Economy KE, Tung NM, Schapira L, Meisel JL, Partridge AH, Mayer EL. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol. 2014 Aug; 21(8):2506-11. PMID: 24756813.
    Citations: 4     Fields:    Translation:Humans
  36. Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14. PMID: 24197661.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  37. Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9. PMID: 24113744.
    Citations: 4     Fields:    Translation:Humans
  38. Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7. PMID: 24062210.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  39. Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat. 2013 Jul; 140(2):331-9. PMID: 23868188.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  40. Meisel JL, Economy KE, Calvillo KZ, Schapira L, Tung NM, Gelber S, Kereakoglow S, Partridge AH, Mayer EL. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013 Dec; 2(1):297. PMID: 23888269.
    Citations: 2     
  41. Mayer EL, Lin NU. Reply to V. Pitini et al. J Clin Oncol. 2013 Jun 10; 31(17):2225-6. PMID: 23901420.
    Citations:    Fields:    Translation:Humans
  42. Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10. PMID: 23645007.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  43. Mayer EL. Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol Educ Book. 2013; 9-14. PMID: 23714443.
    Citations: 4     Fields:    Translation:Humans
  44. Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78. PMID: 23001754.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  45. Mayer EL, Lin NU. Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab? J Clin Oncol. 2012 Nov 01; 30(31):3769-72. PMID: 22987088.
    Citations:    Fields:    Translation:Humans
  46. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6. PMID: 22826271.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  47. Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA1002. PMID: 28140824.
    Citations:    
  48. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. PMID: 22665533.
    Citations: 134     Fields:    Translation:HumansCellsCTClinical Trials
  49. Mayer EL, Gropper AB, Neville BA, Partridge AH, Cameron DB, Winer EP, Earle CC. Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol. 2012 Jan 10; 30(2):158-63. PMID: 22162585.
    Citations: 17     Fields:    Translation:Humans
  50. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6897-904. PMID: 21903773.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  51. Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, Winer EP, Ellisen LW. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011 May 20; 29(15_suppl):1025. PMID: 28020734.
    Citations:    
  52. Gropper A, Burstein HJ, Harris L, Anderson KS, Gold JM, Younger WJ, Bunnell CA, Najita JS, Winer EP, Mayer EL. Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074. PMID: 28023110.
    Citations:    
  53. Mayer EL, Scheulen ME, Beckman J, Richly H, Poli A, Bhargava P, Duarte A, Cotreau MM, Strahs AL, Dickler MN. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. J Clin Oncol. 2011 May 20; 29(15_suppl):1092. PMID: 28021216.
    Citations:    
  54. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92. PMID: 21482957.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  55. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8. PMID: 21205755.
    Citations: 67     Fields:    Translation:Humans
  56. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104. PMID: 20728696.
    Citations: 30     Fields:    Translation:Humans
  57. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010 Jul 15; 16(14):3526-32. PMID: 20634194.
    Citations: 57     Fields:    Translation:Humans
  58. Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376. PMID: 20497961.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  59. E. Mayer, J. Baurain, J. Sparano, L. Strauss, M. Campone, P. Fumoleau, H. Rugo, A. Awada, O. Sy, A. Llombart . Dasatinib in advanced HER-2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. Journal of Clinical Oncology. 2009; A1011.
  60. Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23. PMID: 19294501.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  61. Mayer EL, Isakoff SJ, Hannagan K, Savoie J, Beckman J, Klement G, Gelman R, Winer EP, Burstein HJ. A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. Proceedings of the 2009 Dana-Farber Harvard Cancer Center Breast Cancer Symposium. 2009.
  62. Mayer EL, Mayer RJ. Oncology: Summary. Intensive Review of Internal Medicine, eds Singh, Loscalzo. 2009; in press.
  63. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009 Jan-Feb; 59(1):56-66. PMID: 19147869.
    Citations: 119     Fields:    Translation:Humans
  64. Mayer, EL, Winer EP. Adjuvant Systemic Therapy: Chemotherapy. Diseases of the Breast, eds Harris, Lippman, Morrow, Osbourne. 2009; In Press.
  65. Mayer EL, Isakoff SJ, Hannagan K, Savoie J, Beckman J, Klement G, Gelman R, Winer EP, Burstein HJ. A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. Breast Cancer Research and Treatment. 2008; A906.
  66. Mayer, E; Kozloff, M; Qamar, R; Klenke, B; Balkissoon, J; Parmar, H; Samant, M; Burstein, H. SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results . Breast Cancer Research and Treatment. 2008; A3126.
  67. Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C . Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Breast Cancer Research and Treatment. 2008.
  68. Rugo HS, Carey LA, Mayer E, Marcom PK, Liu M, Ma C, Storniolo AM, Forero A, Esteva FJ, Wolff AC, Hobday T, Ferraro M, Davidson NE, Winer EP, Moore D, Scott J, Park JW . Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. Breast Cancer Research and Treatment. 2008.
  69. Anderson KS, Hodi FS, Sasada T, Canning C, Hassett M, Mayer E, Hannagan K, Wong J, Colson Y, Shoji B, Najita J, Sibani S, LaBaer J, Winer EP, Dranoff G. A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. Breast Cancer Research and Treatment. 2008.
  70. H. S. Rugo, L. A. Carey, E. Mayer, E. Burrows, J. Scott, D. Moore, J. W. Park. Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. Proceedings of the 2008 ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer. 2008; A2.
  71. Javid SH, Smith BL, Mayer E, Bellon J, Murphy CD, Lipsitz S, Golshan M. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg. 2009 May; 197(5):674-7. PMID: 18789411.
    Citations: 4     Fields:    Translation:Humans
  72. EL Mayer, KD Miller, HS Rugo, JM Peppercorn, LA Carey, N Ryabin, Josephs K, EP Winer, HJ Burstein. A Pilot Study of Adjuvant Bevacizumab after Neoadjuvant Chemotherapy for High-Risk Breast Cancer. Proceedings of the American Society of Clinical Oncology. 2008; 26(15S):A519.
  73. Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Josephs K, Winer EP, Burstein HJ. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519. PMID: 27948554.
    Citations:    
  74. EL Mayer, S Hamell, J Savoie, LM Parker, NU Lin, K Anderson, JV Heymach, R Gelman, P Ivy, EP Winer, HJ Burstein. AZD2171 for Refractory Breast Cancer: a Phase 2 Trial. Proceeding of the 2008 Dana-Farber Harvard Cancer Center breast cancer symposium. 2008.
  75. Mayer EL, Burstein HJ. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200. PMID: 18323544.
    Citations: 1     Fields:    Translation:Humans
  76. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008 Feb 01; 26(4):556-62. PMID: 18180462.
    Citations: 134     Fields:    Translation:Humans
  77. EL Mayer, S Hamell, J Savoie, LM Parker, NU Lin, K Anderson, JV Heymach, R Gelman, P Ivy, EP Winer, HJ Burstein. AZD2171 for Refractory Breast Cancer: a Phase 2 Trial. Breast Cancer Research and Treatment. 2007; A6080.
  78. Carey LA, Mayer E, Marcom PK, Rugo H, Liu M, Ma C, Rimawi M, Storniolo A, Forero A, Esteva F, Wolff A, Ingle J, Ferraro M, Sawyer L, Davidson N, Perou CM, Winer EP. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Research and Treatment. 2007; A307.
  79. Mayer, EL. Advances in Chemotherapy for Metastatic Breast Cancer. US Oncological Disease 2007, issue II. 2007; 58-60.
  80. H. J. Burstein, E. L. Mayer, J. Peppercorn, L. M. Parker, K. Hannagan, B. Moy, J. Younger, L. Schapira, G. Wulf, R. Gelman, E. P. Winer. Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study. Proceedings of the American Society of Clinical Oncology. 2007; A594.
  81. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72. PMID: 17512448.
    Citations: 9     Fields:    Translation:Humans
  82. Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23. PMID: 17439759.
    Citations: 4     Fields:    Translation:Humans
  83. Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Winer EP, Burstein HJ. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. Proceedings of the American Society of Clinical Oncology. 2007; A31870.
  84. Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110. PMID: 17888189.
    Citations: 10     Fields:    Translation:Humans
  85. Mayer EL, Winer, EP. . Aromatase Inhibitors for Breast Cancer Treatment and Prevention. Breast Cancer: Translational Therapeutic Strategies. Lyman G, Burstein HJ, eds. 2007.
  86. Mayer EL, Harris LN, Partridge AH, Gelman RS, Schumer ST, Comanaru RS, Long M, Sampson E, Burstein HJ, Winer EP. Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564. PMID: 27952013.
    Citations:    
  87. Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61. PMID: 16800976.
    Citations: 4     Fields:    Translation:Humans
  88. Mayer E, Harris L, Partridge A, Gelman R, Schumer S, Comanaru R, Long M, Sampson E, Burstein H, Winer E. Combination Therapy with Gefitinib and Capecitabine in Metastatic Breast Cancer (MBC): a Phase I Trial. Proceedings of the American Society of Clinical Oncology. 2006; A10564.
  89. Mayer EL, Burstein HJ. . Adjuvant Trastuzumab for HER2 Overexpressing Breast Cancer. American Journal of Oncology. 2005; 4(10)(Supplement 13):11-19.
  90. Roseman NA, Evans RK, Mayer EL, Rossi MA, Slabaugh MB. Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli. J Biol Chem. 1996 Sep 20; 271(38):23506-11. PMID: 8798559.
    Citations: 4     Fields:    Translation:Cells
  91. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996 Mar 01; 27(3):517-27. PMID: 8606260.
    Citations: 49     Fields:    Translation:Humans
  92. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature. 1995 Feb 02; 373(6513):432-4. PMID: 7830794.
    Citations: 214     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mayer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (252)
Explore
_
Co-Authors (84)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.